a 3051

KY19382 (2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382) is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β( IC50s of 19 and 10 nM, respectively). It activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases.

REGN3051 is a human IgG1 monoclonal antibody (mAb) that targets MERS CoV. It has been shown to reduce lung viral titers in mice expressing human DPP4 and to decrease disease severity and viral replication in the lungs of MERS-CoV infected marmosets. The recommended isotype control is HumanIgG1kappa, Isotype Control.